Treatment of patients with nonsevere and severe coronavirus disease 2019: an evidence-based guideline
Open Access
- 29 April 2020
- journal article
- research article
- Published by CMA Impact Inc. in CMAJ : Canadian Medical Association Journal
- Vol. 192 (20), E536-E545
- https://doi.org/10.1503/cmaj.200648
Abstract
No abstract availableThis publication has 25 references indexed in Scilit:
- Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory SyndromeAmerican Journal of Respiratory and Critical Care Medicine, 2018
- Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised studyThe Lancet Respiratory Medicine, 2017
- Treatment outcomes for patients with Middle Eastern Respiratory Syndrome Coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi ArabiaBMC Infectious Diseases, 2016
- Guidelines International Network: Principles for Disclosure of Interests and Management of Conflicts in GuidelinesAnnals of Internal Medicine, 2015
- IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective studyJournal of Antimicrobial Chemotherapy, 2015
- Hyperimmune IV Immunoglobulin Treatment of 2009 Influenza A(H1N1): ResponseSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2013
- GRADE guidelines: 9. Rating up the quality of evidenceJournal of Clinical Epidemiology, 2011
- GRADE guidelines: 3. Rating the quality of evidenceJournal of Clinical Epidemiology, 2011
- Effectiveness of Ribavirin and Corticosteroids for Severe Acute Respiratory SyndromeThe American Journal of Medicine, 2009
- Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patientsClinical Microbiology & Infection, 2004